Clinical Trial Update: Entecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating entecavir prophylaxis to prevent hepatitis B reactivation in patients with resolved hepatitis B undergoing treatment for …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B
• Non-hodgkin Lymphoma

Drugs mentioned

• Baraclude (entecavir)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Resolved Hepatitis B, CD20 Positive B-cell Lymphoma | Phase 2 | Status: RECRUITING